

Triple Negative Breast Cancer Pathologic Diagnosis and Current Chemotherapy Treatment Options

Bernardo L Rapoport, MD, MMed Int Med (Wits),¹ Simon Nayler, BSc, MBBCh, FCPATH, MMed,² Georgia S Demetriou, MBBCh (Wits), FCP (SA), Cert Med Onc (SA),³ Shun D Moodley, MBBCh (Wits), FCP (SA)⁴ and Carol A Benn, MBBCh (Wits) FCS (SA)⁵

1. Specialist Physician and Medical Oncologist, The Medical Oncology Center of Rosebank, Johannesburg, South Africa; 2. Specialist Histopathologist, Gritzman and Thatcher Inc. and Wits Donald Gordon Medical Center, Johannesburg, South Africa; 3. Specialist Physician and Medical Oncologist, Department of Internal Medicine Division of Medical Oncology, University of the Witwatersrand and Wits Donald Gordon Medical Center, Johannesburg, South Africa; 4. Specialist Physician and Medical Oncologist, University of the Witwatersrand and Wits Donald Gordon Medical Center, Johannesburg, South Africa; 5. Specialist Surgeon, Netcare Milpark Hospital Breast Centre and Helen Joseph Hospital, University of the Witwatersrand, Johannesburg, South Africa

Citation: *Oncology & Hematology Review*, 2014;10(2):iii [online only]

Erratum to: *Oncology & Hematology Review*, 2014;10(1):25–32

In order to comply with the latest recommendations outlined by ICMJE the publisher would like to make the following amendments to the Disclosure section:

Bernardo L Rapoport, Simon Nayler, Georgia S Demetriou, Shun D Moodley and Carol A Benn have no conflicts of interest to declare. No funding was received in the publication of this article.